FREEPORT, N.Y., Aug. 1 /PRNewswire/ -- AGI Dermatics (AGI), the pioneer in DNA science for skin, announced today that Robert L. Van Nostrand has agreed to join its management team as Executive Vice President and Chief Financial Officer.
"Bob brings invaluable experience in corporate financing and in building a biotech company into a top tier performer," said Daniel B. Yarosh, Ph.D., AGI Dermatics CEO and Chairman. "We look forward to his leadership in executing our business strategies to grow AGI Dermatics into a preeminent dermatology company."
Mr. Van Nostrand was most recently the Senior Vice President and Chief Compliance Officer of OSI Pharmaceuticals . Bob served for over ten years as its Chief Financial Officer during his tenure at OSI while playing an integral role in raising over $1.4 billion in capital.
"AGI Dermatics is a company that I believe possesses the essential elements of well-respected science and a compelling marketing position which can lead to success," said Mr. Van Nostrand. "As the company continues to move to its next phase of becoming a premier dermatology company, I am looking forward to working with Dan and the management team in fulfilling this goal."
Mr. Van Nostrand serves on the public company boards of Achillion Pharmaceuticals, Inc., Apex Bioventures, Inc., and Metabolix, Inc. Mr. Van Nostrand will continue his service as Chairman of the New York Biotechnology Association. He also sits on the boards of the Cold Spring Harbor DNA Learning Center and the Foundation Board of Farmingdale College.
AGI Dermatics is the bio-pharmaceutical laboratory that has led the research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell-signaling in skin. The company's brand, Remergent, advances the link between science and beauty with products targeting long-term gain through prevention, repair, and restoration. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. www.agiderm.com
AGI DermaticsCONTACT: Liz Mefford, liz.mefford@rprny.com, Courtney McGeever,courtney.mcgeever@rprny.com, both of Rpr Marketing Communications,+1-212-317-1462
Web site: http://www.agiderm.com//
